Download presentation
Presentation is loading. Please wait.
Published byVerawati Pranata Modified over 5 years ago
1
Would Patients With Hemophilia B Benefit From Switching to Extended Half-Life Factor Products?
3
Introduction/Overview
4
Prophylaxis is the Recommended Therapeutic Regimen
5
Key Unmet Needs in Hemophilia B
6
Potential Barriers to Adherence in Hemophilia B Prophylaxis
7
Extended Half-Life Agents and Treatment Individualization
8
The Importance of Maintaining Trough Levels to Prevent Breakthrough Bleeding
9
Pharmacokinetics of 3 Extended Half-Life Agents
10
Improving Adherence in Hemophilia B
11
Higher Factor Activity Levels Can Reduce Average Number of Joint Bleeds
12
Any Joint Bleeding May Be Too Much Joint Bleeding
13
rFIX Molecules With Extended Half-Lives
14
rFIX-FP
15
PROLONG: FIX Activity After Injection of a Single Dose of rFIX-FP or Previous FIX Product (PK Population)
16
PROLONG: AsBR: Prophylaxis Patients
17
PROLONG: Safety Results
18
rFIX-Fc
19
B-LONG: rFIX-Fc Fusion Protein: PK Results
20
B-LONG: Median ABR
21
B-LONG: Safety Results
22
Kids B-LONG: Study Results
23
Glycol PEGylated rFIX
24
PARADIGM 2 N9-GP: Annualized Bleeding Rates Results
25
PARADIGM 2 N9-GP: Mean Predose FIX Activity
26
PARADIGM 5 N9-GP: Overview of Results
27
Prolonged Exposure to PEGylation in PWH-B: Cause For Concern?
28
Relevance of Differences Among the 3 Extended Half-Life rFIX Agents
29
Switching Patient From Standard to Extended Half-Life rFIX Agents
30
Summary and Conclusions
31
Abbreviations
32
Abbreviations (cont)
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.